Onco360 has been selected by AstraZeneca Pharmaceuticals as a national pharmacy partner for Zegfrovy, a targeted lung cancer medicine. The Onco360 pharmacy partnership, announced in October 2026, expands the companies’ relationship and gives the specialty pharmacy a role in supporting treatment access and ongoing patient care.

Key Takeaways

  • AstraZeneca selected Onco360 as a national pharmacy partner for Zegfrovy, also known as sunvozertinib.
  • The stated indication covers a specific mutation-defined group of adults whose lung cancer has progressed after platinum-based chemotherapy.
  • The announcement did not disclose financial terms or an expected revenue contribution.

Onco360 pharmacy partnership focuses on treatment access

Onco360’s national pharmacy partner announcement, dated October 12, 2026, identifies AstraZeneca as the company selecting the pharmacy for Zegfrovy. It describes Onco360 as a national partner, not an exclusive distributor.

Chief Commercial Officer Benito Fernandez said the expanded relationship would use Onco360’s oncology platform to support treatment access, personalized care and ongoing patient support.

Onco360 is headquartered in Louisville, Kentucky, and dispenses medicines nationally through accredited oncology pharmacies. It is a specialty pharmacy brand of PharMerica Corporation. The announcement establishes an additional product partnership but provides no financial figures with which to assess its commercial size.

Zegfrovy serves a defined lung cancer population

Zegfrovy, the brand name for sunvozertinib, is indicated for adults with locally advanced or metastatic non-small cell lung cancer carrying epidermal growth factor receptor exon 20 insertion mutations, as detected by an FDA-approved test. Patients must have experienced disease progression on or after platinum-based chemotherapy.

That treatment setting is important: the pharmacy appointment is not an announcement of a broader first-line indication. Although Onco360 also discussed a trial in previously untreated patients, those findings concern a different treatment setting from the indication described in the partnership announcement.

The medicine is a kinase inhibitor targeting EGFR. Onco360 also noted its inclusion in National Comprehensive Cancer Network guidelines as a subsequent therapy option for patients with this mutation-defined form of advanced or metastatic lung cancer.

Read More News

More FinanceVelix news

Disclaimer

This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.